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Abstract  1 
Objective: The aim of this study was twofold; to develop a dichorionic twin pregnancy 2 
specific reference range for placental growth factor, and to compare gestational 3 
specific placental growth factor levels in twin pregnancies later complicated by 4 
preeclampsia, hypertensive disorder of pregnancy or fetal growth restriction to controls 5 
 6 
Design: Prospective observational study  7 
 8 
Setting: Single large tertiary maternity unit in Ireland  9 
 10 
Population or Sample: Women with a twin pregnancy 11 
 12 
Methods: Consenting pregnant women, across a variety of gestations, had a single 13 
blood sample taken at one time point only during their pregnancy. The plasma was 14 
initially biobanked and PlGF was measured later in batches using the point of care 15 
Triage® PlGF test 16 
 17 
Main Outcome Measures: Development of preeclampsia, hypertensive disorder of 18 
pregnancy or fetal growth restriction  19 
 20 
Results: PlGF levels in uncomplicated dichorionic twin pregnancies were significantly 21 
lower in the women who later developed preeclampsia than in the controls at all 22 
gestational intervals.  In those that later developed any hypertensive disorder of 23 





while in infants with a customised birthweight below the 3rd centile, PlGF was lower 1 
only in those sampled after 24 weeks’ gestation. 2 
 3 
Conclusions: PlGF levels in twin pregnancy differ significantly between those women 4 
with a pregnancy that will later be complicated by preeclampsia and those that will not. 5 
This difference is present many weeks before clinical signs or symptoms of disease 6 
are present. Using cross sectional values from uncomplicated twin pregnancies, we 7 
have developed a dichorionic twin pregnancy specific reference range for PlGF. 8 
 9 
Funding: The Irish Centre for Fetal and Neonatal Translational Research (INFANT), 10 
Cork, Ireland provided financial support for this study. The funder had no role in the 11 
study design; collection, analysis or interpretation of data; or in the writing of the report; 12 
or in the decision to submit the article for publication 13 
 14 
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Preeclampsia is a common complication of pregnancy characterised by new onset 2 
hypertension and either proteinuria or other maternal organ dysfunction after 20 3 
weeks’ gestation (1). Along with other hypertensive disorders of pregnancy (HDP), it 4 
is a major contributor to maternal and neonatal morbidity and mortality (2, 3). 5 
Potentially serious maternal morbidity may arise in the form of seizures, cerebral 6 
haemorrhage, renal failure, liver rupture and disseminated intravascular coagulation 7 
(4).  The only definitive treatment for preeclampsia is removal of the placenta, often 8 
resulting in iatrogenic pre-term delivery and subsequent fetal morbidity (5).  Women 9 
with a twin pregnancy are at a two to three fold increased risk of developing 10 
preeclampsia, possibly due to a combination of larger placental mass and use of 11 
assisted reproductive therapy (ART), especially use of non-autologous gametes (6-8). 12 
Rates of twin pregnancy have risen over the last number of decades globally (9-12).   13 
Although the exact aetiology of preeclampsia is not fully understood, a growing body 14 
of evidence suggests that an imbalance of angiogenic factors of placental origin play 15 
a crucial role in its development (13-17). Placental growth factor (PlGF) is an 16 
angiogenic protein and a member of the vascular endothelial growth factor family (18).  17 
Studies in singleton pregnancies have shown lowered levels of PlGF and increased 18 
levels of its soluble receptor sFlt-1 in maternal plasma, weeks prior to the clinical onset 19 
of preeclampsia (19, 20). The UK National Institute for Clinical Excellence (NICE) 20 
advocates PlGF testing, combined with routine clinical care, to help rule out pre-term 21 
preeclampsia in singleton pregnancies  (21). A number of international randomised 22 
control trials (RCTs) are currently on-going, investigating the clinical impact of the 23 
integration of PlGF into clinical care pathways (22). The international INSPIRE trial 24 





preeclampsia and showed that use of the ratio, in conjunction with standard clinical 1 
practice, significantly improved clinical precision without changing admission rates 2 
(23). The UK PARROT study, demonstrated a reduction in time taken to diagnosis 3 
preeclampsia and reduced maternal morbidity when PlGF is integrated into clinical 4 
care algorithms (24). 5 
Few studies to date have evaluated the levels of circulating angiogenic factors during 6 
twin pregnancy. In those that have been described, huge variations exist in; the 7 
primary outcome (i.e preeclampsia, fetal growth restriction or other adverse clinical 8 
outcome); the definition/classification of the primary outcome; the gestational age at 9 
time of sampling; and the immunoassay used for quantification. (25-33). The aim of 10 
this study was twofold; to develop a dichorionic twin pregnancy specific reference 11 
range for PlGF and secondly to compare gestational specific PlGF levels in twin 12 
pregnancies complicated by preeclampsia, any hypertensive disorder of pregnancy 13 
(HDP) or fetal growth restriction to controls.  14 
 15 
Materials & Methods 16 
Setting and Design 17 
This study was conducted in a single maternity hospital in Ireland with over 8000 18 
deliveries per annum. The study was a prospective cross-sectional cohort study of 19 
PlGF in twin pregnancy. From the start of July 2015 to the end of December 2017, 20 
women attending the hospital’s dedicated twin pregnancy clinic were approached to 21 
participate in the study. Any woman with an uncomplicated twin pregnancy from 12+0-22 
36+6 weeks’ gestation inclusive, without signs/symptoms or a diagnosis of 23 





congenital anomaly in either baby, severe early onset growth restriction or twin-to-twin 1 
transfusion syndrome (TTTS) were excluded from recruitment. Following informed 2 
patient consent, a 3ml ethylenediaminetetraacetic acid (EDTA) blood sample was 3 
taken, centrifuged, divided into aliquots and the plasma biobanked at -80C within 3 4 
hours of sampling. All sampling, processing and biobanking was carried out within the 5 
same building according to previously published Standard Operating Procedures 6 
(SOPs) (34). Women had venepuncture performed at one random gestational time 7 
point only. Clinically relevant outcome data such as the diagnosis of any HDP (chronic 8 
hypertension, gestational hypertension, preeclampsia or superimposed preeclampsia) 9 
and infant birthweights were taken from medical notes following delivery. Anonymised 10 
clinical and demographic data pertaining to the participant and their offspring were 11 
recorded in the study database. For our study, the NICE definitions of hypertensive 12 
disorders of pregnancy were utilised (35).Fetal growth restriction was calculated based 13 
on actual birthweight, gestation at birth, fetal gender and maternal ethnicity, parity and 14 
BMI using the Gestation Related Optimal Weight (GROW) centile calculator (36). 15 
Patients were not involved in the development of this research study and a core 16 
outcome set was not used.  17 
Placental Growth Factor Immunoassay 18 
Biobanked plasma samples were analysed in batches for circulating levels of PlGF 19 
using a point of care immunoassay; the Triage® PlGF test (Quidel Inc., San Diego). 20 
This test is not routinely available in the hospital for clinical use. It was purchased by 21 
our research centre for the purpose of this study. The test manufacturers had no part 22 
in the study design, conduct, analysis or manuscript development. The immunoassay 23 
was performed as per manufacturer’s instructions, in a single freeze thaw cycle to 24 





approximately 15 minutes and have a measurable range from 12-3000 pg/ml. The 1 
Triage® has a reported measurable range from 12-3000 pg/ml. The manufacturers 2 
report total precision on plasma controls at concentrations of 85.2 and 1300 pg/mL as 3 
12.8% and 13.2% respectively. For the purposes of this study, any result obtained <12 4 
pg/ml was allocated the value of 10 pg/ml.  5 
Statistics 6 
SPSS Version 23 and Stata 15 were used to analyse the data.  7 
Part 1: Descriptive statistics were employed to examine the baseline maternal 8 
demographics, clinical outcomes and the PlGF distribution in the cohort. When 9 
developing a reference range for PlGF, all cases where a stillbirth was diagnosed in 10 
either of the twins as well as cases where any form of HDP later developed were 11 
removed. Secondly in order to facilitate development of a reference range for PlGF in 12 
an uncomplicated dichorionic twin pregnancy all monochorionic twin pregnancies were 13 
removed. Lastly, cases that developed fetal growth restriction resulting in both twins 14 
having a customised birthweight of less than the 3rd centile were then removed. The 15 
remaining women were divided according to gestational age at recruitment and PlGF 16 
ranges calculated for each gestational week were calculated. A heterogeneous 17 
regression of log(PlGF) on gestational age of was used to develop a reference range 18 
for PlGF in uncomplicated dichorionic twin pregnancies.. The mean of log(PlGF) was 19 
modelled using fractional polynomials and the variance was modelled as proportional 20 
to some power of gestational age (37). The residuals were assumed to follow a Normal 21 
distribution at each gestational age. Centiles of log(PIGF) were exponentiated to yield 22 





Part 2: To examine the effect of hypertensive disorders and placental dysfunction on 1 
PlGF, the entire cohort including abnormal cases, was divided into 2 groups based on 2 
the woman’s gestational age at time of her enrolment to the study and hence sampling 3 
of maternal plasma PlGF; <24 weeks’ gestation and ≥ 24 weeks’ gestation. This 4 
gestational cut-off was employed as pregnancy related hypertensive complications are 5 
unusual prior to this timepoint and also it equated well with the median of the cohort.   6 
 7 
Results 8 
In total, 275 women with a twin pregnancy were recruited. There were no withdrawals 9 
or losses to follow up. Three women (1% of the cohort) had a stillbirth occur in one of 10 
the twins while in 4.7% (n=12) of women, an anomaly of one or both twins was 11 
diagnosed. Given with twin pregnancy there is differing placental volumes present 12 
dependent on chorionicity, circulating levels of PlGF may also vary in line with 13 
chorionicity. We found that PlGF was lower in monochorionic twin pregnancy (data not 14 
shown) but given the high incidence of complications as well as the small numbers 15 
present (n=40) in this subgroup, further analysis was not possible. We limited our 16 
analysis to dichorionic cases only for development of the reference range. 17 
 18 
Part 1:  19 
Reference Range Demographics 20 
Removal of those with an abnormal pregnancy outcome (preeclampsia or HDP in the 21 
mother, stillbirth of either twin or where both twins had a customised birthweight of <3rd 22 





dichorionic twin pregnancy for inclusion in the reference range analysis (Supplemental 1 
Material Figure 1). Median maternal age was 34 years, booking BMI was <30Kg/m2 2 
for the majority (81.5%; n=141) and most were Caucasian (93.6%; n=162). Over half 3 
of the group were multiparous (56.1%; n=97), just over a third (35.1.1%; n=60) had 4 
conceived the twin pregnancy with use of ART. All women with pre-existing renal 5 
disease or essential hypertension developed superimposed preeclampsia in their 6 
pregnancies and hence were not included in the reference range cohort (Supplemental 7 
Material Table 1). Comparison of participant characteristics between each gestational 8 
group showed no significant difference in enrolment characteristics (Supplemental 9 
Material Table 2).  10 
Reference Range Development  11 
The 3rd-97th centiles of PIGF as a function of gestational age concentrations were 12 
calculated (Table 1). With progressing gestational age the median PlGF was seen to 13 
rise, simultaneously to the development and maturation of the placentae, peaking at 14 
25 weeks gestation, and then steadily decreased towards term. The lowest acceptable 15 
PlGF value for each gestational week is presented (Figure 1). Removal of cases where 16 
women developed any form of HDP or where both twins had a customised birthweight 17 
<3rd centile did not alter the reference range significantly. These data provide a valid 18 
reference range for PlGF in a normal dichorionic twin pregnancy (Figure 2).  19 
 20 
Part 2: 21 
Comparison of Gestational PlGF  22 
The second aim of this study was to compare gestational PlGF in twin pregnancies 23 
complicated by preeclampsia, HDP or customised birthweight of both twins <3rd 24 





based on the woman’s gestational age at time of her enrolment to the study and hence 1 
gestational age at time of sampling of maternal plasma PlGF; <24 weeks’ gestation 2 
and ≥ 24 weeks’ gestation.  Just under half the cohort (43.6%; n=120) were recruited 3 
at <24 weeks’ gestation with the remainder (56.4%, n=155) recruited at ≥ 24 4 
gestational weeks.  The groups were then stratified by presence of preeclampsia, HDP 5 
or customised birthweight <3rd centile for both infants.  6 
 7 
Demographics of Entire Cohort 8 
The maternal age of the study group ranged from 20 to 50 years, with 134 women 9 
(48.7%) aged >35 years at booking. The majority of the cohort had a Body Mass Index 10 
(BMI) of <30Kg/m2 at booking (78.9%; n=217) and were of Caucasian ethnicity 11 
(93.8%; n=258). Just under half the cohort were nulliparous (46.9%; n=129). The 12 
majority of the group were dichorionic twin pregnancies (81.5%; n=224) and 13 
approximately two thirds (65.5%; n=180) of the population studied had conceived the 14 
twin pregnancy spontaneously. Where assisted reproductive therapy (ART) was 15 
utilised, almost a fifth (17.1%; n=47) had conceived through the assistance of In Vitro 16 
Fertilisation (IVF) and a large proportion of these using a donor oocyte (12%; n=33).  17 
There was a small number of women with pre-existing renal disease or hypertension 18 
(1.8%; n=5). The two gestational groups were well matched, with no differences seen 19 
in BMI <30, ethnicity, parity or chorionicity. However, there were significantly more 20 
women with ART assisted pregnancies (40.2%; n=48 v 27.8%; n=42, p=0.04), oocyte 21 
donation (18.5%; n=22 v 7.3%; n=11, p=0.009) and those with a maternal age >35 22 
years (57.5%; n=69 v 41.9%; n=65, p=0.01) sampled in the <24 weeks’ gestational 23 






Clinical Outcomes  1 
Overall, the incidence of a subsequent diagnosis of HDP was 15.3% (n=42) and of 2 
these 11.3% (n=31) developed preeclampsia (Supplemental Material Table 4). Of the 3 
532 infants with maternal BMI information available, 11.8% (n=65)  had a customised 4 
birthweight <3rd centile with both twins <3rd customised birthweight in twelve cases. 5 
Gestation at delivery ranged from 23 to 38 weeks’ gestation, with two thirds of the 6 
cohort delivered via Caesarean section (66.5%, n=183). Pre-term delivery at <35 7 
weeks occurred in almost a fifth of the cohort (17.8%, n=49) and in over half of cases 8 
was iatrogenic (59.2%, n=20). Preterm delivery at <32 weeks was less common (6.9%, 9 
n=19), and again half of cases were iatrogenic (47.4%, n=9). There were no significant 10 
differences between the two gestational groups in terms of incidence of HDP or 11 
preeclampsia, nor were there any differences in pre-term delivery or mode of delivery. 12 
 13 
Comparison of PlGF   14 
The median PlGF was 230.5 pg/mL when sampling occurred at <24 weeks and 276 15 
pg/mL when sampling was ≥24 weeks. The cohort was then stratified by subsequent 16 
diagnosis of preeclampsia, HDP or customised birthweight <3rd centile in both twins. 17 
PlGF levels were 0.6 times higher in the controls than in the women who later 18 
developed preeclampsia at <24 weeks gestation (247 pg/ml vs 153 pg/ml) and 2.0 19 
times higher at >24 weeks gestation (304 pg/ml vs 99.8 pg/ml.)(Table 2). In those that 20 
subsequently developed any form of HDP, PlGF was 0.7 times higher in the >24 weeks 21 
group (250 pg/ml vs 150 pg/ml) (Table 3). In those that subsequently had either twin 22 
born at a birthweight <3rd customised centile, PlGF was 0.8 times higher in the group 23 







Main Findings 2 
 This study demonstrates that maternal plasma PlGF in twin pregnancy follows the 3 
same gestational pattern as described in singletons (38, 39); a steady rise 4 
corresponding with development of the placenta, peaking slightly earlier at 5 
approximately 25 weeks’ gestation, and then declining thereafter. It also shows that 6 
maternal plasma PlGF is significantly lower in twin pregnancies that will later develop 7 
preeclampsia but not other HDP, independent of gestational age at time of sampling 8 
of PlGF, compared to controls. PlGF was also noted to be lower in those babies with 9 
a customised birthweight <3rd centile when maternal sampling occurred after 24 10 
weeks gestation.  11 
Interpretation 12 
To our knowledge, this is the largest prospective study of PlGF in twin pregnancy from 13 
a single site. This allows us to describe the twin pregnancy specific distribution of 14 
gestational PlGF, as well as develop a dichorionic specific reference range for PlGF 15 
in twin pregnancy, which has not been previously described. This is also the only study 16 
to date examining PlGF in twin pregnancies specifically using the Triage® PlGF test. 17 
The Triage® PlGF test is currently the only point of care test on the market for 18 
measuring PlGF, is CE marked and has been endorsed by NICE for use in further 19 
research (21).  20 
Previous studies of angiogenic factors in twin pregnancy have had limited numbers of 21 
participants, varied gestations at quantification, varied outcome measures and often 22 
involve pooled results from a number of sites or countries across a variety of time 23 





other countries, which may affect the quality of samples. In contrast, all of the 1 
laboratory analysis in our study was performed on site, by a single researcher, in a 2 
single freeze thaw cycle, to minimise the chance of protein denaturation.  3 
A Spanish study in 2011 examined first trimester levels of circulating angiogenic 4 
factors in 61 women with a twin pregnancy (40). Using a R&D systems immunoassay, 5 
they reported higher serum concentrations of both PlGF and sFlt-1 in twins compared 6 
to matched singletons. They also reported maternal serum sFlt-1 levels were higher 7 
in twin pregnancies conceived through ART compared to spontaneous twin 8 
conceptions, supporting the well-accepted concept that ART pregnancies are at 9 
increased risk of preeclampsia development.  10 
A study from Boston in 2012 (41) described 79 women with a twin pregnancy 11 
presenting with suspected preeclampsia in the third trimester. Serum PlGF and sFlt-1 12 
from the women was quantified using the Roche Elecsys immunoassay Ratio test.  13 
The outcome measure utilised was the diagnosis of an adverse clinical event in the 14 
subsequent fortnight, of which 52 women met the criteria. The authors reported 15 
median PlGF was significantly reduced, while median sFlt-1 was elevated in those that 16 
did develop an adverse event indicating that these angiogenic factors have potential 17 
utility as prognostic indicators in twin pregnancies with suspected preeclampsia. 18 
A German group in 2014 published on a small cohort of 49 women with a twin 19 
pregnancy, 18 of which developed preeclampsia. Maternal serum PlGF and sFlt-1 was 20 
quantified again using the Roche Elecsys immunoassay Ratio test. The researchers 21 
reported PlGF levels were decreased and sFlt-1 levels increased in the preeclampsia 22 





controls, indicating the potential for integration of angiogenic factors into clinical care 1 
pathways for investigation of suspected preeclampsia in twin pregnancy (42).  2 
Clearly, potential exists for use of PlGF and sFlt-1 as biomarkers for prediction of 3 
preeclampsia in twin pregnancies. However, before these biomarkers are introduced 4 
into clinical use for twins, it is important that relevant cut-offs are developed and 5 
validated specifically for this group and specific to each PlGF platform. Differences in 6 
PlGF results may arise between commercially available platforms owing to 7 
measurement of different PlGF isoforms by each assay gene (43). The Triage 8 
immunoassay predominantly measures PlGF Isoform-1, the R&D System assay 9 
detects PIGF-2 and PIGF-3 isoforms in addition to PlGF-1 while the Roche is a ratio 10 
of PlGF to sFLT-1 (44, 45).  11 
Several large prospective observational studies have published on clinically relevant 12 
cut-offs for use in singletons. The PROGNOSIS study, using the Roche Elecsys 13 
immunoassay Ratio test in 550 women with suspected pre-eclampsia, reported a sFlt-14 
1:PlGF ratio of ≤38 as having a negative predictive value for preeclampsia in 15 
singletons in the subsequent 7 days of 99.3% (46). The PELICAN study, using the 16 
Triage® PlGF test in 625 women with suspected pre-eclampsia, reported a PlGF of 17 
>100 pg/ml as having a 98% negative predictive value for preeclampsia in the 18 
subsequent 14 days in singletons presenting at < 35 weeks’ gestation (47).  19 
A 2018 Dutch study compared PlGF and sFlt-1 levels in normotensive and pre-20 
eclamptic singleton and twin pregnancies using the Roche Elecsys immunoassay 21 
Ratio test (48). Numbers were small, with only 22 twin pregnancies included. Again, 22 
differences in serum sFlt-1 and PlGF levels were noted in the normotensive twins 23 





the twin controls. Importantly, they demonstrated that the previously defined sFlt-1 
1/PlGF ratio cut-off of ≤38 for predicting short-term absence of preeclampsia in 2 
singleton pregnancies is not applicable to twin pregnancies. Importantly this 3 
demonstrates that established reference ranges for PlGF/sFlt-1 in singletons are not 4 
transferrable to twin or higher order multiple pregnancies. This highlights the need for 5 
quality prospective observational studies of women with twin pregnancy presenting 6 
with suspected preeclampsia, in order to develop and validate clinically useful cut-offs 7 
for PlGF/sFlt-1 in twins.  8 
It appears there may be a role for PlGF in identification of pathologically related growth 9 
restriction in twin pregnancy, given the lower PlGF levels we observed in the maternal 10 
plasma of those women that later went on to deliver babies <3rd CBW centile. Studies 11 
in singleton pregnancies have demonstrated the utility of PlGF in discriminating 12 
pathological growth restriction from constitutional smallness and in the prediction of 13 
adverse perinatal outcomes (49, 50). 14 
Strengths and Limitations. 15 
 We recognise there are limitations to our study specifically the use of a customised 16 
birthweight centile not specific to twin pregnancy and the exclusion of cases where 17 
only both twins were <3rd customised centile. This choice was pragmatic given our 18 
numbers however we recognise that reduced placental volume in either twin may 19 
affect the circulating maternal PlGF levels. Normal twin growth patterns are the subject 20 
of much debate with differing opinion as to which is the most appropriate growth curve 21 
to use in clinical  practice (51, 52). Concerns exist that twin specific growth charts, 22 
adjusted to reflect the smallness of twins compared to singletons, may not identify 23 





increased perinatal morbidity (53). There is no consensus as to whether fetal growth 1 
charts should be customised by factors such as ethnicity, height, weight and parity or 2 
not and there is also no agreement regarding which is the most appropriate growth 3 
calculator to use (54-59).  4 
A second limitation of the study was single sampling of participants. Serial sampling 5 
of maternal PlGF may have provided a much more robust, informative account of PlGF 6 
distribution. However repeated phlebotomy, solely for the purposes of a research 7 
study, may have deterred many women from taken part and given that participation 8 
was truly altruistic, a single timepoint only approach was adopted. Our population is 9 
largely homogenous; white Caucasian and non-obese which potentially limits 10 
extrapolation to minority ethnic groups however this is representative of the twin 11 
pregnancy population that attends our unit. Although a large number of women with a 12 
twin pregnancy were enrolled, we do not have sufficient power at present to develop 13 
a monochorionic twin pregnancy specific reference range, although it would be 14 
possible to expand on the study and add to our numbers in the future to achieve this.  15 
An additional limitation of our study is the use of only one automated commercial 16 
platform for quantification of PlGF alone and not s-FLT1, rather than on multiple 17 
commercially available platforms such as the DELFIA Xpress PlGF 1-2-3 test, Brahms 18 
Kryptor and the Roche Elecsys ratio test, as advocated by NICE (21). Comparative 19 
studies performed in singleton pregnancies have shown similar performance of all 20 
three platforms in ability to rule out preeclampsia (60). As sufficient plasma remains 21 
biobanked in our site, this is an area for potential future research subject to funding 22 






We have shown that PlGF levels in twin pregnancy differ between those pregnancies 1 
that later will be complicated by preeclampsia and those that will not. This difference 2 
is present many weeks before clinical signs or symptoms of disease are present. We 3 
provide a valid overall reference range for PlGF in a normal twin pregnancy and 4 
specifically in a normal dichorionic twin pregnancy. With further research, PlGF has 5 
potential as an adjunct to clinical care as a predictor of evolving preeclampsia and/or 6 
adverse clinical outcomes in twin pregnancy. 7 
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Figure 1: Scatter plot of gestational PlGF. Shaded area represents the reference range from the 5th to 95th percentiles (n=222). 







Figure 2: Scatter plot of gestational PlGF for the uncomplicated dichorionic twin pregnancy cohort. Shaded area represents the reference 







Table 1: Normal Reference Range percentiles of PlGF by gestational age interval quantified using the Triage® PlGF test (n=173) 




(pg/ml)         
 3rd 5th 10th 25th 50th 75th 90th 95th 97th 
12 3.0 3.5 4.3 6.3 9.5 14.5 21.0 26.2 30.3 
13 5.5 6.3 8.0 11.8 18.1 27.8 40.9 51.5 59.9 
14 9.3 10.9 13.8 20.6 32.1 50.0 74.6 94.7 110.7 
15 15.0 17.6 22.5 33.9 53.6 84.7 127.9 163.7 192.1 
16 22.7 26.8 34.5 52.8 84.5 135.4 206.9 266.6 314.4 
17 32.8 38.8 50.3 77.8 126.2 204.8 316.5 410.7 486.5 
18 44.8 53.3 69.7 108.9 178.9 293.8 459.3 600.0 713.7 
19 58.5 69.8 91.8 145.1 241.1 400.8 633.3 832.7 994.7 
20 72.7 87.1 115.3 184.1 309.6 520.7 831.3 1100.0 1319.4 
21 86.2 103.8 138.2 223.0 379.3 645.2 1040.7 1385.5 1668.4 
22 97.9 118.3 158.5 258.2 444.0 763.7 1244.1 1666.1 2014.0 
23 106.4 129.1 173.9 286.0 497.2 864.4 1422.0 1915.3 2324.1 
24 110.8 134.9 182.8 303.5 533.3 936.8 1555.7 2107.4 2566.6 
25 110.7 135.3 184.3 308.9 548.2 973.0 1630.8 2221.4 2715.2 
26 106.2 130.2 178.3 301.6 540.7 969.5 1639.6 2245.4 2754.2 
27 97.8 120.4 165.8 282.9 512.1 927.3 1582.1 2178.3 2681.0 
28 86.7 107.0 148.1 255.0 466.1 852.1 1466.5 2029.5 2506.3 
29 73.9 91.5 127.3 221.0 407.9 752.7 1306.5 1817.3 2251.7 
30 60.6 75.4 105.3 184.4 343.4 639.6 1119.5 1565.0 1945.3 
31 47.9 59.7 83.9 148.1 278.3 523.1 923.1 1296.8 1617.1 
32 36.5 45.6 64.4 114.6 217.3 412.0 732.9 1034.6 1294.1 
33 26.8 33.6 47.6 85.4 163.4 312.6 560.6 795.0 997.5 
34 19.0 23.9 34.0 61.4 118.5 228.7 413.2 588.7 740.9 
35 12.9 16.3 23.4 42.6 82.9 161.3 293.6 420.3 530.5 
36 8.5 10.8 15.5 28.5 55.9 109.7 201.3 289.4 366.3 
Centiles were calculated based on a Normal distribution for log(PIGFR) where  
𝜇𝜇 = 𝑒𝑒𝑒𝑒𝑒𝑒 �−19.8165 + 6.9434 × √𝐺𝐺 − 0.01375 × 𝐺𝐺2� 







Table 2: PlGF by gestational group at enrolment in twin pregnancies complicated by A Preeclampsia (de novo or superimposed) compared to those  
that were not, quantified using the Triage® PlGF test (n=275) 
Gestation at recruitment 
(weeks) 
Median (IQR) PlGF  
pg/mL (n=275) 
Median (IQR) PlGF  
 PEA present pg/mL (n=31) 
Median (IQR) PlGF  
 PE not present pg/mL (n=244) 
<24 230.5 (79.4-437.8) 153 (54-224) 247 (81-489) 
≥24 276 (71.6-577) 99.8 (24-273) 304 (73-652) 
  
Table 3: PlGF by gestational group at enrolment in twin pregnancies complicated by B Hypertensive Disorder of Pregnancy   compared to those that  
were not, quantified using the Triage® PlGF test (n=275)  
Gestation at recruitment 
(weeks) 
Median (IQR) PlGF  
pg/mL  
(n=275) 
Median (IQR) PlGF 
 HDPB present pg/mL  
(n=42) 
Median (IQR) PlGF  
 HDP not present pg/mL  
(n=233) 
<24 230.5 (79.4-437.8) 150 (45-229) 250 (84-490) 
≥24 276 (71.6-577) 123 (32-425) 304 (73-598) 
 
Table 4: PlGF by gestational group at enrolment in offspring of twin pregnancies complicated by C birthweight <3rd customised centile compared to  
those that were not, quantified using the Triage® PlGF test (n=532)  
Gestation at recruitment 
(weeks) 
Median (IQR) PlGF  
pg/mL (n=532)* 
Median (IQR) PlGF pg/mL 
 CBW <3rdC  
(n=109) 
Median (IQR) PlGF pg/mL 
 CBW not <3rdC   
(n=423) 
<24 230.5 (79.4-437.8) 234 (54.2-460.5) 231 (105-413) 
≥24 276 (71.6-577) 170 (42.7-462) 304 (73-652) 
*BMI not available for 9 women so CWB not available for 18 offspring 
 
